31 May 2024 - EMA has recommended granting a marketing authorisation in the European Union for Ixchiq, the first vaccine in the EU to protect adults 18 years and older against Chikungunya. It is given as a single dose.

Considering the significant global public health implications of this vaccine, Ixchiq was assessed under EMA’s OPEN initiative that fosters international collaboration and sharing of scientific expertise to promote global public health.

Read EMA press release